Fig. 5

YTHDC1 inhibits the activation of the MAPK signaling pathway by targeting ANXA1 in ccRCC. A-D, The 786-O and A498 cells were transfected with indicated constructs for 48 h. Cells were harvested for western blot analysis (A), CCK-8 assay (B), transwell assay (C and D). Data presents as mean ± SD with three replicates. Ns, not significant; *, P < 0.05; ***, P < 0.001. E-I, The 786-O and A498 cells were transfected with indicated shRNAs for 72 h. After puromycin selection, cells were harvested for western blot analysis (E), CCK-8 assay (F), tranwell assay (G and H) and colonformation assay. Data presents as mean ± SD with three replicates. Ns, not significant; *, P < 0.05; ***, P < 0.001. J and K, 786-O cells were transfected with indicated shRNAs for 72 h. After puromycin selection, cells were collected and subcutaneously injected into the nude mice. The tumor mass and tumor growth curve were shown in panel J and panel K. Data presents as mean ± SD with six replicates. Ns, not significant; *, P < 0.05; ***, P < 0.001